Sunrise at Stonehenge draws Druids, pagans and revelers to celebrate the summer solstice
The solstice is one of the few occasions each year when visitors are allowed to walk among the stones, which are otherwise fenced off. The crowd gathered before dawn at the World Heritage Site to mark the start of summer in the Northern Hemisphere, beating the heat during the UK's first amber heat-health alert issued since September 2023. Temperatures later topped 33 degrees Celsius (91.4 degrees Fahrenheit) in Surrey, 80 miles (128 kilometers) east of Stonehenge–the hottest temperature recorded in the UK this year.
About 25,000 sun devotees and other revelers, including druids, pagans, hippies, locals and tourists, showed up, according to English Heritage, which operates the site. More than 400,000 others around the world watched a livestream. 'This morning was a joyous and peaceful occasion with the most beautiful sunrise,' said Richard Dewdney, head of operations at Stonehenge. 'It is fantastic to see Stonehenge continuing to enchant and connect people.'
Stonehenge was built in stages 5,000 years ago on the flat lands of Salisbury Plain, approximately 75 miles (120 kilometers) southwest of London. The unique stone circle was erected in the late Neolithic period, about 2500 B.C. Some of the so-called bluestones are known to have come from the Preseli Hills in southwest Wales, nearly 150 miles (240 kilometers) away, and the altar stone was recently discovered to have come from northern Scotland, some 460 miles (740 kilometers) away.
The site's meaning has been vigorously debated. Theories range from it being a coronation place for Danish kings, a druid temple, a cult center for healing or an astronomical computer for predicting eclipses and solar events. The most generally accepted interpretation is that it was a temple aligned with movements of the sun–lining up perfectly with the summer and winter solstices.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arab News
17-07-2025
- Arab News
How quantum computing and AI can accelerate and improve drug development
RIYADH: Using traditional discovery processes, a staggering 90 percent of drug development trials are unsuccessful. But what if there is a future in which quantum technologies could revolutionize that process to achieve unprecedented efficiency? The race to develop quantum computers has been surging worldwide. In April, IBM announced a $150 billion investment plan to strengthen US technologies and innovation over the next five years, including a push for quantum computer development. Additionally, the UK's National Quantum Technologies Programme has invested more than £1 billion in quantum technology since its establishment in 2014, with facilities such as the National Quantum Computing Centre. PASQAL in France is also a leading company in quantum research. In 2024, Saudi Aramco signed an agreement with PASQAL to deploy the first quantum computer in the Kingdom, scheduled to be up and running by the end of this year. If the promise of quantum computing holds, the pharmaceutical industry could be looking at faster, more accurate, and less costly drug discovery and development. The World Health Organization predicts that antimicrobial resistance to existing drugs will lead to 10 million human deaths by 2050. To stop the timer, the pharmaceutical industry must adopt new and innovative technologies. Artificial intelligence has already had a huge impact on the efficiency and success of clinical trials, generating new materials and computationally predicting their performance rather than relying on scientists' intuition for molecular hypotheses that then must be synthesized and tested repeatedly. Quantum computing, however, has the potential to take it one step further. It uses special units called qubits (quantum bits), which can exist in multiple states at once and can link together in unique ways, to perform computations much more efficiently than classical computers. In layman's terms, quantum computers solve complicated problems quicker while AI simplifies the problem and then solves it. Quantum computers understand the problem. AI does not. A research scientist focusing on computational catalysis with a doctoral degree in chemical engineering spoke to Arab News about the current feasibility of this tool. 'We are talking about mature technology (AI) versus very immature technology (quantum),' he said. According to the World Economic Forum, in synergy, quantum computing and AI can lead to enhanced molecular understanding. Although our expert heeds that 'we are not at the stage where we can actually do that, we can only do it on very specific problems because there are many physical limitations… you need to be able to manipulate atoms in a very precise way that we currently cannot do.' Quantum physics allows scientists to predict the behavior of electrons in molecules, producing detailed three-dimensional structural insight into new drug designs. Rather than adopting traditional laborious methods such as X-ray crystallography, quantum principles and AI provide virtual simulations. AI further accelerates this process by quickly analyzing datasets and clinical outcomes to pin down favorable drug targets and predict a compound's efficacy. A novel tool called quantum machine learning combines AI's power of data analysis and pattern recognition with quantum computing's ability to simulate complex molecular behavior throughout trillions of possibilities. This paves the way to more accurate and faster predictions in drug binding orientation, absorption, and metabolic pathways. QML makes it possible to sift through vast chemical spaces holding trillions of potential drug candidates in weeks or days in contrast to the years that classical computers would need. With the integration of quantum computing and AI, compound screening traditionally executed 'in vitro,' meaning outside of a living organism, can be done 'in silico' instead, meaning carried out in virtual simulations. A new quantum-AI model developed by Qubit Pharmaceuticals with Sorbonne University and announced in May of this year called FeNNix-Bio1, reportedly leverages unprecedented computational power and very accurate molecular databases. Employing the principles of quantum mechanics (such as superposition and entanglement), quantum computers can model molecular and atomic behavior with great accuracy and speed. This is critical to understanding relevant properties such as molecular stability, binding affinity, and how drugs could interact with target proteins in real-world conditions. Structural optimization and docking — determining how a drug candidate fits into a biological target, can be simplified using QML and quantum-powered algorithms. These algorithms rapidly evaluate orientations of molecules against target structures to identify optimal configurations, and which molecules will bind most effectively. This enhances drug absorption and metabolic stability. Quantum computing and AI models are then able to streamline the preclinical phase, delivering only the most promising compounds to laboratory validation, significantly reducing tedious lab work and enabling researchers to conduct faster and cheaper work. And with more accurate early-stage predictions, overall success of clinical trials is boosted, lab to market time is reduced, and the possibility of delivering targeted treatments for unmet patient needs is increased. 'You do patient trials to reduce the risk of anything going wrong with the patient, imagine if you are able to accurately predict how the drug will affect people without doing a trial. This will create a leap in how we produce drugs and how we can commercialize drugs,' our expert said. Meeting specific patient needs based on their biological profiles rather than producing drugs for a wide demographic can drastically change our healthcare systems and how we consume products. Patients will be able to get a drug for diseases such as Alzheimer's, diabetes, cancer, and more without having to wait ten years for a trial to decide their fate. You can also anticipate what conditions or illnesses people are at high risk of developing later in life and treat them early on, such as joint pain and hair loss. It comes down to significant time reduction and improved chances of success. 'A quantum computer can significantly increase my accuracy. My chances of success are very dependent on my prediction of the performance. 'The quantum computer can make more accurate calculations that can make my predictions of the performance much more accurate. By doing that, my chances of success will be higher. 'Another way is that a quantum computer will be much faster in performing tasks, generating structures and predicting their performance than AI, and by that I will reduce my time further.' Although we are still a long way from achieving this, the functionality of quantum computing and AI theorizes that personalized medicine and treatments for patients is possible. 'If (specific patient information) becomes accessible to those companies… then they match that information to their database, hypothetically speaking it is possible.' Although this all sounds like the realms of sci-fi, there have been significant strides in this area of quantum research. Pfizer and its partner XtalPi, a US-China pharmaceutical tech company, reportedly used quantum-inspired algorithms and AI cloud computing to reduce 3D structure prediction time of new molecules from months to days, enabling rapid assessment of candidate molecules and their drug-likeness. Additionally, it is said that Qubit Pharmaceuticals' FeNNix-Bio1 quantum AI model could be used for QML applications such predicting toxicity, side effects, and drug metabolism with greater speed and accuracy. Taking it into perspective, our expert said: 'Three years ago, no one would have thought we would have a large language model that can perform as well as ChatGPT does today, it came out of left field. A breakthrough could happen.' However, WEF warns that before this technology can become the new commercial norm, certain guardrails need to be put in place to ensure the safe, effective, and responsible use of this novel tool. Data integrity and avoiding bias, ethical and regulatory oversight, workforce readiness training, and a shared vision for applying best practices all must be upheld industry wide.
Arab News
16-07-2025
- Arab News
Healthy babies born in Britain after scientists used DNA from three people to avoid genetic disease
LONDON: Eight healthy babies were born in Britain with the help of an experimental technique that uses DNA from three people to help mothers avoid passing devastating rare diseases to their children, researchers reported Wednesday. Most DNA is found in the nucleus of our cells, and it's that genetic material — some inherited from mom, some from dad — that makes us who we are. But there's also some DNA outside of the cell's nucleus, in structures called mitochondria. Dangerous mutations there can cause a range of diseases in children that can lead to muscle weakness, seizures, developmental delays, major organ failure and death. Testing during the in vitro fertilization process can usually identify whether these mutations are present. But in rare cases, it's not clear. Researchers have been developing a technique that tries to avoid the problem by using the healthy mitochondria from a donor egg. They reported in 2023 that the first babies had been born using this method, where scientists take genetic material from the mother's egg or embryo, which is then transferred into a donor egg or embryo that has healthy mitochondria but the rest of its key DNA removed. The latest research 'marks an important milestone,' said Dr. Zev Williams, who directs the Columbia University Fertility Center and was not involved in the work. 'Expanding the range of reproductive options … will empower more couples to pursue safe and healthy pregnancies.' Using this method means the embryo has DNA from three people — from the mother's egg, the father's sperm and the donor's mitochondria — and it required a 2016 UK law change to approve it. It is also allowed in Australia but not in many other countries, including the US Experts at Britain's Newcastle University and Monash University in Australia reported in the New England Journal of Medicine Wednesday that they performed the new technique in fertilized embryos from 22 patients, which resulted in eight babies that appear to be free of mitochondrial diseases. One woman is still pregnant. One of the eight babies born had slightly higher than expected levels of abnormal mitochondria, said Robin Lovell-Badge, a stem cell and developmental genetics scientist at the Francis Crick Institute who was not involved in the research. He said it was still not considered a high enough level to cause disease, but should be monitored as the baby develops. Dr. Andy Greenfield, a reproductive health expert at the University of Oxford, called the work 'a triumph of scientific innovation,' and said the method of exchanging mitochondria would only be used for a small number of women for whom other ways of avoiding passing on genetic diseases, like testing embryos at an early stage, was not effective. Lovell-Badge said the amount of DNA from the donor is insignificant, noting that any resulting child would have no traits from the woman who donated the healthy mitochondria. The genetic material from the donated egg makes up less than 1 percent of the baby born after this technique. 'If you had a bone marrow transplant from a donor … you will have much more DNA from another person,' he said. In the UK, every couple seeking a baby born through donated mitochondria must be approved by the country's fertility regulator. As of this month, 35 patients have been authorized to undergo the technique. Critics have previously raised concerns, warning that it's impossible to know the impact these sorts of novel techniques might have on future generations. 'Currently, pronuclear transfer is not permitted for clinical use in the US, largely due to regulatory restrictions on techniques that result in heritable changes to the embryo,' Williams, of Columbia, said in an email. 'Whether that will change remains uncertain and will depend on evolving scientific, ethical, and policy discussions.' For about a decade, Congress has included provisions in annual funding bills banning the Food and Drug Administration from accepting applications for clinical research involving techniques, 'in which a human embryo is intentionally created or modified to include a heritable genetic modification.' But in countries where the technique is allowed, advocates say it could provide a promising alternative for some families. Liz Curtis, whose daughter Lily died of a mitochondrial disease in 2006, now works with other families affected by them. She said it was devastating to be told there was no treatment for her eight-month-old baby and that death was inevitable. She said the diagnosis 'turned our world upside down, and yet nobody could tell us very much about it, what it was or how it was going to affect Lily.' Curtis later founded the Lily Foundation in her daughter's name to raise awareness and support research into the disease, including the latest work done at Newcastle University. 'It's super exciting for families that don't have much hope in their lives,' Curtis said.
Al Arabiya
26-06-2025
- Al Arabiya
Denis Villeneuve to direct next James Bond film
Denis Villeneuve is going from Dune to Bond. Amazon MGM announced Wednesday that Villeneuve will direct the next James Bond movie. The untitled film will be the first since the studio took creative reins of the storied film franchise after decades of control by the Broccoli family. Producers Amy Pascal and David Heyman had maintained that before the next Bond is cast, they would develop a screenplay and find a director first. Now they have one of the most respected blockbuster makers in Hollywood who's coming off a pair of widely acclaimed Dune films. In a statement, Villeneuve said he grew up watching Bond movies. 'I'm a die-hard Bond fan. To me, he's sacred territory,' said Villeneuve. 'I intend to honor the tradition and open the path for many new missions to come. This is a massive responsibility, but also incredibly exciting for me and a huge honor.' Since taking creative control of Bond in February, Amazon MGM has worked quickly to get the next movie going. The studio is also trying to win over fans skeptical of the new corporate leadership of 007 and the likelihood of future spinoffs. 'James Bond is in the hands of one of today's greatest filmmakers,' said Mike Hopkins, head of Prime Video and Amazon MGM Studios. 'With Pascal and Heyman lodged as producers and Villeneuve behind the camera, the next Bond movie will have an enviable brain trust.' Villeneuve beat out a field of directors floated for the movie, including Edward Berger (Conclave), Paul King (Paddington 2), Edgar Wright (Baby Driver), and Jonathan Nolan, co-creator of Westworld and brother to Christopher Nolan. 'Denis Villeneuve has been in love with James Bond movies since he was a little boy,' said Pascal and Heyman. 'It was always his dream to make this movie, and now it's ours, too.'
